Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Asco 2023 – Elevation follows in Astellas’s slipstream
There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 ADC, but no such good news for Zai Lab’s zolbetuximab challenger.
Asco 2023 preview – a microcap winner
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.